Ozempic Vision Loss Lawsuit

Do You Have an Ozempic Vision Loss Case?

The Barnes Firm is reviewing Ozempic, Wegovy, Rybelsus, and Mounjaro vision loss cases nationwide in 2026 for people who have developed serious vision loss or blindness after using these medications. If you’ve suffered vision loss from a GLP-1 medication, you may have legal options.

People diagnosed with nonarteritic anterior ischemic optic neuropathy (NAION), sudden blindness, or other optic nerve damage after using these drugs may qualify for compensation. Thousands of cases are now pending in federal court.

Ask yourself:

• Have you used Ozempic, Wegovy, Rybelsus, or Mounjaro?
• Did you develop sudden vision loss, blurry or dim vision, or other vision problems while taking the medication?
• Were you diagnosed within the last few years?

If yes, call The Barnes Firm at (800) 800-0000 or fill out a secure online form for a free consultation. There are no fees unless the firm recovers compensation for you.

What Is Ozempic and How Do GLP-1 Drugs Work?

Ozempic is an injectable semaglutide medication FDA-approved in 2017 to treat type 2 diabetes. Ozempic is commonly prescribed to treat diabetes and is also used off-label as a weight management drug. It is also widely prescribed off-label as a weight loss drug, leading to increased adverse event reports.

GLP-1 receptor agonists mimic glucagon-like peptide-1, increasing insulin release, suppressing glucagon, slowing gastric emptying, and reducing appetite. These effects help manage blood sugar and support weight loss. These medications are part of a new class of weight loss medications and are increasingly prescribed for chronic weight management to help patients lose weight.

Related GLP-1 drugs in similar lawsuits include Wegovy, Rybelsus, Saxenda, Victoza, Mounjaro, and Zepbound.

Many patients are prescribed Ozempic for both diabetes and weight loss, and the rapid adoption of these weight management drugs has led to increased scrutiny. Rapid adoption from 2022 to 2025 outpaced research into long-term risks.

Why People Are Filing Ozempic Vision Loss Lawsuits

Lawsuits claim drug manufacturers Novo Nordisk and Eli Lilly failed to warn about serious vision risks. A growing number of lawsuits have been filed against these drug manufacturers and drug companies due to severe adverse reactions, including vision loss. Plaintiffs argue the companies knew or should have known about these dangers.

Claims include failure to warn, defective design, and negligent misrepresentation. Lawsuits claim Novo Nordisk failed to adequately warn of the risk of vision loss or optic neuropathy associated with Ozempic.

The main injury is sudden vision loss from Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and other optic nerve damage. Many lawsuits are claiming that patients suffered injuries as a result of taking Ozempic.

Many plaintiffs say they would have chosen different medications or declined off-label use if fully informed. Plaintiffs allege deceptive marketing practices that downplayed serious risks and overstated the drug’s benefits for off-label weight loss.

Key Allegations Against Manufacturers

Lawsuits focus on failure to provide timely warnings about NAION and permanent optic nerve damage. Early labels mentioned “vision changes” but not permanent damage. Plaintiffs lawyers argue that Novo Nordisk knew or should have known about the risks of Nonarteritic Anterior Ischemic Optic Neuropathy (NAION) and failed to warn patients. Plaintiffs argue clinical trial red flags, post-marketing reports, and EMA safety actions warranted earlier U.S. warnings.

Some complaints allege aggressive marketing minimized risks while promoting weight-loss benefits.

The Barnes Firm investigates each case individually to match specific vision injuries and drug use to these broader allegations, building a personalized legal strategy for every client.

Ozempic and Vision Loss (NAION and Other Eye Injuries)

Anterior ischemic optic neuropathy (“eye stroke”) occurs when blood flow to the optic nerve is blocked, causing sudden, painless, often permanent vision loss. NAION is the non-inflammatory form.

Studies report a higher risk of NAION among semaglutide users, especially in patients with type 2 diabetes treated with semaglutide. A 2024 JAMA Ophthalmology study found increased NAION rates in semaglutide patients.

The WHO and EMA recognize NAION as a rare but serious side effect. In August 2024, EMA updated semaglutide labeling to include vision loss risk.

Common warning signs include:

• Sudden blurred or dim vision in one eye
• Loss of part of the visual field
• Rapid vision loss over hours or days
• No pain with vision changes

Anyone experiencing acute vision problems on these drugs should seek emergency care and preserve ophthalmology records.

Who Qualifies to File an Ozempic Vision Loss Lawsuit?

Eligibility depends on documented drug use, qualifying vision injuries, and state statutes of limitations.

Qualifying injuries include:

• NAION or optic nerve damage causing partial or total blindness
• Sudden “eye stroke” symptoms diagnosed by an ophthalmologist

Permanent or long-lasting vision injuries receive priority.

Contact The Barnes Firm for a free case review online or at (800) 800-0000.

Medical and Documentation Requirements

Important documents include:

• Pharmacy records showing drug use
• Hospital and ophthalmology records confirming vision loss or NAION
• Imaging and visual field tests
• Treatment notes
• Financial documents proving lost wages

Early documentation is critical due to statutes of limitations. Maintaining a symptom log and timeline can also help strengthen your claim.

Current Ozempic Vision Loss Lawsuit Status and Timeline

Most federal Ozempic and GLP-1 vision loss cases are consolidated in MDL No. 3163 in the Eastern District of Pennsylvania, created in December 2025 to centralize related lawsuits. The Judicial Panel on Multidistrict Litigation (JPML) oversees the consolidation of these cases as part of a mass tort, the court overseeing MDL 3094 had earlier limited that proceeding to GI injuries, and the JPML later agreed to centralize NAION cases separately rather than add them to the current litigation.

Judge Karen S. Marston presides, issuing key rulings on case management and expert standards. The judicial panel plays a key role in assigning judges and managing the multidistrict litigation process.

An MDL groups individual lawsuits for pretrial proceedings but preserves separate claims. Numerous lawsuits involving Ozempic claims are being coordinated as part of the ongoing Ozempic litigation, and as of January 2026, there have been no global settlements or public jury verdicts in the Ozempic multidistrict litigation.

Vision Loss Litigation: NAION Tracks and State-Court Actions

Since mid-2025, litigation focus shifted toward NAION and vision loss claims. Plaintiffs seek a dedicated “Vision Injury Track” within the MDL. This track will involve claims related to NAION and other vision injuries.

In New Jersey, plaintiffs petitioned for multicounty litigation (MCL) to coordinate NAION claims, with at least 20 cases coordinated as of early 2026.

Consolidation streamlines pretrial processes but does not guarantee settlement. The litigation is still in its early stages, with key decisions and actions yet to occur. Resolution depends on court rulings and negotiations.

Key Timeline Milestones

• Sept 2023: FDA adds ileus warning to Ozempic label.
• Feb 2024: MDL 3094 created.
• 2024 JAMA study central to evidence.
• Dec 2025: MDL No. 3163 created

The Barnes Firm monitors developments to keep clients informed.

Contact The Barnes Firm Today

If you or a loved one has experienced vision loss, permanent blindness, or severe gastrointestinal injuries after taking Ozempic or other GLP-1 weight loss drugs, don’t wait to seek legal help. Time is limited due to strict filing deadlines, and early action can protect your rights. Contact our trusted team at The Barnes Firm for a free consultation. Our team will guide you through the legal process, help gather your medical records, and fight to secure the compensation you deserve for medical expenses, lost wages, and pain and suffering. Reach out today to explore your options and take the first step toward justice.